(3S)-(-)-acetamidopyrrolidine | 131776-41-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (3S)-(-)-acetamidopyrrolidine
• 英文别名: acetamidopyrrolidine；N-pyrrolidin-1-ylacetamide
• CAS: 131776-41-5
• 化学式: C₆H₁₂N₂O
• 分子量: 128.174
• InChiKey: XSFMNFYLWHPZIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3S)-(-)-acetamidopyrrolidine 、 2-(4-methoxyphenylazo)-1,3-dimethyl-3H-imidazol-1-ium perchlorate 、 异丙醇 生成 2-[4-(3-Acetamidopyrrolidine-1-yl)phenylazo)-1,3-dimethyl-3H-imidazol-1-ium perchlorate
  参考文献：
  名称：

  Dyeing composition for dyeing keratinous fibres comprising a cationic azo-dye

  摘要：

  本发明涉及一种新型染料组合物，用于染色角质蛋白纤维，特别是人类头发，包括式(I)的阳离子偶氮染料：W1-N═N—W2-W3，以及使用该组合物的染色方法和式(I)的新化合物。

  公开号：

  US20040107513A1

文献信息

• Novel processes for the preparation of adenosine compounds and intermediates thereto
  申请人：——

  公开号：US20030069423A1

  公开（公告）日：2003-04-10

  Novel processes for the preparation of adenosine compounds and intermediates thereto. The adenosine compounds prepared by the present processes may be useful as cardiovascular agents, more particularly as antihypertensive and anti-ischemic agents, as cardioprotective agents which ameliorate ischemic injury or myocardial infarct size consequent to myocardial ischemia, and as an antilipolytic agents which reduce plasma lipid levels, serum triglyceride levels, and plasma cholesterol levels. The present processes may offer improved yields, purity, ease of preparation and/or isolation of intermediates and final product, and more industrially useful reaction conditions and workability.

  新型的制备腺苷化合物及其中间体的方法。通过本方法制备的腺苷化合物可能作为心血管药物有用，更具体地作为降压和抗缺血药物，作为改善缺血性损伤或心肌梗死大小的心脏保护剂，以及作为降脂剂，可降低血浆脂质水平、血清甘油三酯水平和血浆胆固醇水平。本方法可能提供改善产率、纯度、制备和/或中间体和最终产品的分离的便利性，以及更具工业应用的反应条件和可操作性。
• [EN] ARYLPYRAZOLES AND ARYLISOXAZOLES AND THEIR USE AS PKD MODULATORS<br/>[FR] ARYLPYRAZOLES ET ARYLISOXAZOLES ET LEUR UTILISATION EN TANT QUE MODULATEURS DE LA PROTÉINE KINASE C (PKD)
  申请人：NOVARTIS AG

  公开号：WO2011009484A1

  公开（公告）日：2011-01-27

  The present invention provides novel organic compounds of formula (I) or (Ia): which may be inhibitors of a selective subset of kinases belonging to the AGC or calmodulin kinase family, such as for example PKD-1/2/3, inhibitors of histone deacetylase (HDAC) phosphorylation, or inhibitors of other kinases. The selectivity of which would depend on the structural variation thereof, and for treatment of a disorder or disease mediated by those selected AGC or calmodulin family kinases. These organic compounds can be used to treat various PKD associated states such as heart failure, colorectal cancer, regulation of cell growth, autoimmune disorders, or hyperproliferative skin disorders.

  本发明提供了化学式(I)或(Ia)的新型有机化合物：这些化合物可能是AGC或钙调素激酶家族中的一部分激酶的抑制剂，例如PKD-1/2/3，组蛋白去乙酰化酶（HDAC）磷酸化的抑制剂，或其他激酶的抑制剂。其选择性取决于其结构变化，用于治疗由这些选定的AGC或钙调素家族激酶介导的疾病或疾病。这些有机化合物可用于治疗各种PKD相关状态，如心力衰竭、结直肠癌、细胞生长调节、自身免疫性疾病或过度增生性皮肤疾病。
• [EN] FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS<br/>[FR] DÉRIVÉS DE THIOPHÈNE CONDENSÉS SERVANT D'INHIBITEURS DE MEK
  申请人：UCB PHARMA SA

  公开号：WO2009093013A1

  公开（公告）日：2009-07-30

  A series of 7-oxo-4,5,6,7-tetrahydrothieno[2,3-c]pyridine derivatives, and analogues thereof, which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.

  一系列在2位被取代苯胺基团取代的7-氧代-4,5,6,7-四氢噻吩[2,3-c]吡啶衍生物及其类似物，是人类MEK（MAPKK）酶的选择性抑制剂，在医学上具有益处，例如在治疗炎症性、自身免疫性、心血管、增殖性（包括肿瘤学）和疼痛性疾病方面。
• [EN] INHIBITORS OF CYTOCHROME P450<br/>[FR] INHIBITEURS DE CYTOCHROME P450
  申请人：GILEAD SCIENCES INC

  公开号：WO2012088156A1

  公开（公告）日：2012-06-28

  The present application provides for a compound of formula I, or a salt thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional therapeutic agent.

  本申请提供了一种化合物，其具有I式结构，或其盐类，含有此类化合物的组合物，包括施用此类化合物的治疗方法，以及包括与至少一种其他治疗剂联合施用此类化合物的治疗方法。
• [EN] TRIAZINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE TRIAZINE EN TANT QU'INHIBITEURS DE KINASES
  申请人：UCB PHARMA SA

  公开号：WO2010100405A1

  公开（公告）日：2010-09-10

  A series of substituted [1,3,5]triazin-2-yl derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

  一系列取代的[1,3,5]三嗪-2-基衍生物，作为选择性PI3激酶酶抑制剂，在医学上具有益处，例如在治疗炎症性、自身免疫性、心血管、神经退行性、代谢性、肿瘤学、疼痛或眼科疾病方面。